ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0559 • ACR Convergence 2024

    Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry

    Diego Benavent1, Victor Fanjul2, Sytske Anne Bergstra3, Floris van Gaalen4, Maxime Dougados5, Umut Kalyoncu6, Denis Poddubnyy7, Clementina López Medina8, Konstantinos Parperis9, David Vega-Morales10, Desiree van der Heijde11 and Victoria Navarro Compán12, 1Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 2Savana Research, Madrid, 3LUMC, Leiden, Netherlands, 4LUMC, Leiden, Zuid-Holland, Netherlands, 5Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 6Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 7Charite-Universitatsmedizin Berlin, Berlin, Germany, 8Reina Sofia University Hospital, Cordoba, Spain, 9University of Cyprus Medical School, Nicosia, Cyprus, 10Instituto Mexicano del Seguro Social, Monterrey, México, Monterrey, Mexico, 11Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 12La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) frequently experience unforeseen disease flares that impact their quality of life. Identification of patients with high risk of flares…
  • Abstract Number: 1109 • ACR Convergence 2024

    Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women

    Laura Scagnellato1, Antonio Collesei2, Sonia farah3, Carlomaurizio Montecucco4, Francesca Oliviero5, Bernd raffeiner6, Marta favero5, Amelia Damasco5, doria Andrea5, Fausto Salaffi3 and Roberta Ramonda7, and SIR Study Group on Crystal Arthropaties, 1Rheumatology Unit, University of Padova, Padova, Italy, 2IRCCS Istituto Oncologico Veneto IOV, Padova, Italy, 3Polytechnic University of Marche, Jesi (AN), Italy, 4IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 5University of Padova, Padova, Italy, 6General Hospital of Bolzano, Bolzano, Italy, 7Rheumatology Unit, University of Padova, Italy, Padova, Italy

    Background/Purpose: Crystal arthropaties, including gout and calcium pyrophosphate deposition disease (CPPD), are prevalent and burdensome conditions. The ALLSTAR model allows the identification of reliable causal,…
  • Abstract Number: 1368 • ACR Convergence 2024

    Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India

    Prabhu Vasanth1, John Mathew2 and Divya K3, 1Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, 2Christian Medical college , Vellore , India, Vellore, India, 3Christian Medical College, Vellore, Tamil Nadu, India

    Background/Purpose: Conventional synthetic DMARDs remained the mainstay of treatment of RA for decades. However, their use has decreased recently due to the emergence of biological…
  • Abstract Number: 1632 • ACR Convergence 2024

    Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?

    Augustine Jose1, Molly Thabah2, Chengappa Kavadichanda3, Jagan K L2, Christina Mariaselvam4 and Vir Singh Negi5, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, 2Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, 4JIPMER, Puducherry, Puducherry, India, 5AIIMS, Bilaspur, Puducherry, Puducherry, India

    Background/Purpose: Ultrasonography can measure vascular intimal-medial thickness (IMT) and delineate the degrees of stenosis in Takayasu arteritis (TAK). Further, higher IMT has been reported in…
  • Abstract Number: 1581 • ACR Convergence 2024

    Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation

    shiri keret1, Lisa Kaly2, Georg Schett3, Christina Bergmann4, Joerg Henes5, Gleb Slobodin2 and Doron Rimar2, 1Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 2Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 4Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, 5University Hospital Tuebingen, Tuebingen, Germany

    Background/Purpose: Baseline high Neutrophil- to- lymphocyte ratio (NLR) (higher than 2.95) is associated with severe progressive skin and lung disease and with reduced 5-year survival…
  • Abstract Number: 1613 • ACR Convergence 2024

    Adherence to Dietary Recommendations and the Risk of Developing Giant Cell Arteritis; A Nested Case-Control Study

    Poi Kwanyuen1, Karin Wadström1, Emily Sonestedt1, Charlotta Fors1, Rebecka Bäcklund1, Aladdin Mohammad2, Lennart TH Jacobsson1 and Carl Turesson1, 1Lund University, Malmö, Sweden, 2Lund University, Lund, Sweden

    Background/Purpose: Giant cell arteritis (GCA) affects large and medium-sized vessels in elderly individuals. Previous studies have reported associations with lower body mass index and lower…
  • Abstract Number: 1628 • ACR Convergence 2024

    Tocilizumab for Giant Cell Arteritis in Japan over 2 Years: A Multicenter Retrospective Study

    Nobuhiro Oda1, Sho Fukui2, Toshihiro Yamaguchi3, Fumika Nagase4, Takanori Ito5, Mitsuru Watanabe5, Yoichiro Haji4, Yasuhiro Suyama6, Atsushi Nomura7, Eishi Uechi8, Masei Suda3, Naoho Takizawa4, Ryo Rokutanda9 and Hiromichi Tamaki10, 1Kameda medical center, Department of Rheumatology, Higashi-cho, Kamogawa, Japan, 2Brigham and Women's Hospital, Brookline, MA, 3Suwa Central Hospital, Department of Rheumatology, Nagano, Japan, 4Chubu Rosai Hospital, Department of Rheumatology, Aichi, Japan, 5Daido Hospital, Department of Rheumatology, Aichi, Japan, 6NTT Medical Center Tokyo, Department of Rheumatology, Tokyo, Japan, 7Ushiku Aiwa General Hospital, Department of Rheumatology, Ibaraki, Japan, 8Yuai Medical Center, Department of Rheumatology, Okinawa, Japan, 9Kameda medical center, Department of Rheumatology, Chiba, Japan, 10St. Luke’s International Hospital, Immuno-Rheumatology Center, Tokyo, Japan

    Background/Purpose: The GiACTA trial, a phase III global trial of tocilizumab (TCZ) for giant cell arteritis (GCA), did not involve Japanese patients, and real-world data…
  • Abstract Number: 1523 • ACR Convergence 2024

    Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020

    Husam El Sharu, East Carolina University, Greenville, NC

    Background/Purpose: Introduction: In the past decade, the incidence of Lupus Nephritis (LN) flares linked to mortality has generally decreased, though an upward trend has emerged…
  • Abstract Number: 1592 • ACR Convergence 2024

    Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes

    Federica Pallotti1, Camille Mettler2, Roberto Padoan3, Francesca Regola4, Franco Franceschini5, Sergey Moiseev6, Pavel Novikov7, Mario Andrea Piga8, Gianluca Moroncini9, Silke Brix10, Abdul Hadi Kafagi11, Samuel Deshayes12, Achille Aouba12, Julien Campagne13, Paolo Delvino14, Jan Willem Cohen Tervaert15, Luisa Brussino16, Martin Michaud17, Nils Venhoff18, Federico Alberici19, Claudia Iannone20, Sophie Rosenstingl21, Marin Moutel22, Jean-Marc Galempoix23, Vincent Cottin24, Clara Jaccard25, Diane Riehl26, Paul Legendre27, Anne-Claire Billet28, Paola Parronchi29, Luca Quartuccio30, Vítor Silvestre Teixeira31, Allyson Egan32, David Jayne32, Enrico Tombetti33, Marco Caminati34, Christian Pagnoux35, Alexis Régent36, Marc Ruivard37, Loïc Guillevin38, Xavier Puéchal36 and Benjamin Terrier39, and the French Vasculities Study Group and European EGPA Study Group, 1Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, 2Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, 3Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 4Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, 5Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 6Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia, 7Sechenov First Moscow State Medical University, Moscow, Russia, 8Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Ancona, Italy, 9Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, 10Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom, 11Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom, 12Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, 13Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, 14University of Milano-Bicocca, Milan, Milan, Italy, 15University of Alberta, Edmonton, Canada, 16SSDDU Immunologia Clinica ed Allergologia, AO Mauriziano, Turin, Italy, 17Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, 18Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, 19Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, 20Department of Rheumatology, University of Milan, and Rheumatology Department, ASST Pini-CTO, Milan, Italy, 21Service Médecine Interne, Centre hospitalier intercommunal Compiègne Noyon, Compiègne Noyon, France, 22Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Reims University Hospital, Reims, France, 23J.M. Galempoix, MD, Department of Internal Medicine, Nord Ardennes Hospital, Charleville-Mézières, France, 24Hôpital Louis Pradel, Centre de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Lyon, France, 25Gaston Bourret Hospital, Nouméa, New Caledonia, 26Centre hospitalier intercommunal Toulon- La Seyne Sur Mer, Toulon, France, 27Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, 28Department of Internal Medicine, Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France, 29University of Florence, Florence, Florence, Italy, 30Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 31Department of Rheumatology, Faro Hospital, Algarve, Portugal, 32University of Cambridge, Cambridge, United Kingdom, 33Internal Medicine and Rheumatology, Department of Biomedical and Clinical Sciences, Sacco and Fatebenefratelli Hospitals, Milan, Italy, Milan, Italy, 34Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, 35Mount Sinai Hospital, Toronto, ON, Canada, 36National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 37Internal Medicine Department, Estaing University Hospital, CHU Clermont-Ferrand, Clermonnt-Ferrand, Italy, 38National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 39Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: ANCA-associated vasculitis (AAV) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (EGPA). Although these entities are often easily distinguished in…
  • Abstract Number: 1509 • ACR Convergence 2024

    Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort

    Rosana Quintana1, Guillermo Pons-Estel2, Karen Roberts3, Erika S. Palacios Santillan3, Íñigo Rúa-Figueroa4, José María Pego-Reigosa5, Pablo Ibañez6, Leonel Ariel Berbotto7, Maria Constanza Bertolaccini8, Marina Laura Micelli9, Cecilia Pisoni10, Vitalina De Souza Barbosa11, Henrique de Ataíde Mariz12, Francinne Machado Ribeiro13, Luciana Parente14, Emília Sato15, Milena Mimica Davet16, Gustavo Aroca Martínez17, Fabio Bonilla-Abadía18, Gerardo Quintana López19, Reyna E. Sánchez Briones20, Mario Pérez Cristóbal21, Luis H. Silveira Torre22, Ignacio García De La Torre23, Ivan Morales Avendaño24, Pablo Gamez-Siller25, Astrid Paats26, Jorge N. Cieza Calderón27, Andy Armando Mendoza Maldonado28, Martin Rebella29, Gonzalo Silveira30, John Fredy Jaramillo31, Monica Sanchez32, Urbano Sbarigia33, Ashley Orillion34, Federico Zazzetti35, Graciela Alarcon36 and Bernardo Pons-Estel37, and Grupo Latino Americano de Estudio del Lupus (GLADEL), 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 3Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 5Galicia Health Service (SERGAS), Vigo, Spain, 6Servicio de Reumatología del HIGA San Martín, La Planta, Argentina, 7Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, 8Servicio de Reumatologia - Hospital Angel C. Padilla, San Miguel de Tucumán, Argentina, 9Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, 10CEMIC, Buenos Aires, Argentina, 11Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, 12Universidad Federal de Pernambuco, Recife, Brazil, 13Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 14Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 15Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 16Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, 17Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, 18Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 19Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, 20División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, 21Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, 22Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 23Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, 24Hospital Central Dr. Ignacio Morones Prieto, Potosi, Mexico, 25Servicio de Reumatologia del Hospital Universitario, "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 26Hospital de Clínicas I, Asunción, Paraguay, 27Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, 28Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 29Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 30Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, 31Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, 32Unidad Nefrologia,Hospital fernandez, CABA, Argentina, 33Johnson & Johnson Innovative Medicine, Brussels, Belgium, 34Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 35Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 36The University of Alabama at Birmingham, Oakland, CA, 37Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of serious infections, which in turn, are associated with morbidity and mortality. The Systemic…
  • Abstract Number: 1624 • ACR Convergence 2024

    Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement

    Julio Sánchez-Martín1, Javier Loricera2, Isabel Martinez-Rodriguez3, ivan Ferraz-Amaro4, Nestor Martinez-Amador5, Remedios Quirce-Pisano5, Fernando Lopez-Gutierrez6 and Ricardo Blanco-Alonso7, 1Hospital Universitario 12 de Octubre, Madrid, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, 4Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 5Department of Nuclear Medicine, Hospital Universitario Marqués de Valdecilla, Molecular Imaging Group, IDIVAL, Santander., Santander, Spain, 6Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan has become a very useful diagnostic tool in patients with GCA with large vessel involvement. However,…
  • Abstract Number: 1520 • ACR Convergence 2024

    The Influence of Trauma on Features of Type 2 SLE

    Jennifer Rogers1, Megan Clowse2, David Pisetsky3, Jayanth Doss4, Mithu Maheswaranathan5, Lisa Criscione-Schreiber5, Rebecca Sadun4, Kai Sun4 and Amanda Eudy6, 1Duke, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University Medical Center, Durham, NC, 4Duke University, Durham, NC, 5Duke University School of Medicine, Durham, NC, 6Duke University, Raleigh, NC

    Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown.  Since trauma has…
  • Abstract Number: 1626 • ACR Convergence 2024

    Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review

    Sagar Patel1, Iva Okaj2, Jessica Scott3, Sukhreet Atwal3, Colin Stark3, Rabia Tahir3, Nader Khalidi2 and Mats Junek2, 1McMaster University, Brampton, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3McMaster University, Hamilton, Canada

    Background/Purpose: Giant cell arteritis is being increasingly recognized to occur in intracranial vessels. The clinical significance of intracranial GCA (ICGCA) is unknown; previous cases have…
  • Abstract Number: 1594 • ACR Convergence 2024

    Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification

    Michele Moretti1, Francesco Ferro2, Irene Martelli3, Francesca Pistone3, Giulia Greco3, Federica Di Cianni4, Nazzareno Italiano5, ROSARIA TALARICO4, Veronica Seccia6, Chiara Baldini7, Ilaria Puxeddu3 and Marta Mosca7, 1University of Pisa, Pisa, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4University of Pisa, Pisa, Italy, 5University of Pisa, Rovigo, Italy, 6Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, 7University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy

    Background/Purpose: The introduction of Mepolizumab treatment has revolutionized the therapy of EGPA and has promoted the search for biomarkers predictive of response to treatment. However,…
  • Abstract Number: 1529 • ACR Convergence 2024

    Systemic Lupus Erythematous and Neuromyelitis Optica Overlap and Risk of Infection in Hospitalized Patients

    Elizabeth Fagin1, Wei Chapman2, fares Saliba3 and Eugenio Capitle4, 1Staten Island University Hospital, Teaneck, 2Staten Island University Hospital, Staten Island, 3Staten Island University Hospital, Staten Island, NY, 4University Hospital, Newark

    Background/Purpose: Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder that can coexist with systemic lupus erythematous (SLE). Given the immunosuppressive nature of SLE, it is…
  • « Previous Page
  • 1
  • …
  • 293
  • 294
  • 295
  • 296
  • 297
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology